期刊文献+

CYP2C19基因联合血小板功能检测指导复杂PCI术后的抗血小板疗效 被引量:2

CYP2C19 gene combined with platelet function test for guiding the antiplatelet therapy after complex PCI
原文传递
导出
摘要 目的 探讨CYP2C19基因联合血小板功能检测(PFT)指导复杂经皮冠状动脉介入术(PCI)术后抗血小板治疗的应用及其疗效。方法 选取2019年1月至2021年1月因复杂冠状动脉(冠脉)病变于沧州市中心医院行PCI的患者136例进行前瞻性研究,按随机数字表法分为观察组及对照组各68例。PCI术前两组均口服阿司匹林联合氯吡格雷抗血小板治疗,且已达到各300 mg剂量。PCI术后,观察组根据CYP2C19基因检测区分不同代谢型,将中间代谢型进行PFT后的低反应患者以及慢代谢型视为氯吡格雷抵抗,对其双联抗血小板中的氯吡格雷调整为替格瑞洛;对照组仍用阿司匹林和氯吡格雷。观察PCI术后4周血清心肌肌钙蛋白(cTnI)、肌酸激酶同工酶(CK-MB)、超敏C-反应蛋白(hs-CRP)水平,并统计PCI术后1、12个月主要不良心血管事件(MACE)及出血事件。结果 术后4周观察组血清cTnI、hs-CRP及CK-MB水平均低于对照组(P<0.05,P<0.01)。术后1个月,观察组和对照组MACE总发生率比较,差异无统计学意义(2.94%vs 5.88%,P>0.05);术后12个月,观察组MACE总发生率显著低于对照组(8.82%vs 23.53%,P<0.05)。观察组和对照组出血总发生率比较差异无统计学意义(10.29%vs 8.82%,P>0.05)。结论 CYP2C19基因联合PFT在指导复杂PCI术后抗血小板治疗1个月内能改善心肌损伤及炎性指标,并能降低术后12个月内MACE,且不增加总体出血风险。 Objective To investigate the antiplatelet effect of CYP2 C19 gene combined with platelet function test(PFT) after complex percutaneous coronary intervention(PCI).Methods A total of 136 patients with complex coronary artery lesions underwent PCI in Cangzhou Central Hospital from January 2019 to January 2021 were selected for prospective research,and were randomly divided into observation group and control group(n=68,each).Before PCI,aspirin combined with clopidogrel was given in both groups,and the dosage reached 300 mg each.After PCI,in observation group,different metabolic types were distinguished according to the detection of CYP2 C19 gene;the patients with low response after PFT of the intermediate metabolic type and the patients with gene slow metabolic type were considered to be clopidogrel resistance,and the clopidogrel in the dual antiplatelet was adjusted to ticagrelor.In control group,aspirin and clopidogrel were still used.At 4 weeks after PCI,the serum levels of cardiac tmponin I(cTnI),creatine kinase MB isoenzyme(CK-MB) and high-sensitivity C-reactive protein(hs-CRP) were detected,and the major adverse cardiovascular events(MACE) and the bleeding events were observed at 1 month and 12 months after PCI.Results The serum levels of cTnI,hs-CRP and CK-MB in observation group were significantly lower than those in control group(P0.05),however,at 12 months after surgery that in observation group was significantly lower compared with control group(8.82% vs 23.53%,P0.05).Conclusion CYP2 C19 gene combined with PFT can improve myocardial injury and inflammatory indexes within 1 month through guiding antiplatelet therapy after complex PCI,and reduce MACE within 12 months after operation without increasing the bleeding risk.
作者 于建才 彭万忠 刘永兴 姜洋 刘娟 徐泽升 YU Jian-cai;PENG Wan-zhong;LIU Yong-xing;JIANG Yang;LIU Juan;XU Ze-sheng(Department of Cardiology,Cangzhou Central Hospital,Cangzhou,Hebei 061000,China)
出处 《中国临床研究》 CAS 2022年第10期1344-1348,共5页 Chinese Journal of Clinical Research
基金 河北省医学科学研究课题计划项目(20200176)。
关键词 CYP2C19基因 血小板功能检测 慢代谢型 中间代谢型 氯吡格雷抵抗 复杂经皮冠状动脉介入术 抗血小板治疗 CYP2C19 gene Platelet function test Slow metabolic type Intermediate metabolic type Clopidogrel resistance Complex percutaneous coronary intervention Antiplatelet therapy
  • 相关文献

参考文献12

二级参考文献68

  • 1Rajan L,Moliterno DJ. Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Curr Cardiol Rep, 2011,13:303-311. 被引量:1
  • 2Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after pereutaneous coronary interventions : appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol, 2008, 51 : 690-697. 被引量:1
  • 3Lindsey JB, Marso SP, Pencina M, et al. Prognostic importance of bleeding and myocardial infarction after percutaneous coronary intervention in unseleeted patients: result from the EVENT (evaluation of drug-eluting stents and isehemic events) registry. JACC Cardiovasc Interv, 2009, 2: 1074-1082. 被引量:1
  • 4Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2009, 30: 655-661. 被引量:1
  • 5Amlani SNT, Afzal R, Pal-Sayal R, et al. Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. J Thromb Thrombolysis, 2010, 30: 434-440. 被引量:1
  • 6Ndrepepa GSS, Keta D, Mehilli J, et al. Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. Am J Cardiol, 2010, 105 : 163-167. 被引量:1
  • 7Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv, 2009, 2: 222-229. 被引量:1
  • 8Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol, 2009, 53: 2019-2027. 被引量:1
  • 9Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in- hospital bleeding. Circulation, 2008, 118: 2139-2145. 被引量:1
  • 10Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation,2011,123:2736-2747. 被引量:1

共引文献50

同被引文献29

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部